Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by StockWatcher01on Jan 20, 2019 1:04pm
114 Views
Post# 29257087

RE:RE:RE:RE:Clinicals trials?

RE:RE:RE:RE:Clinicals trials?I appreciate this response. I really do believe in PMN like I do with other stocks I am invested in. I’ve sold those as well, some at a loss so that I can reinvest either somewhere else or to buy in at a lower point. I however l, don’t become emotionally attached to a stock. As an investor I see the cards where they lay and make a decision that’s best for me and my money. Someone else is going to be making money instead of me if I choose not to sell at an opportune time. PMN hit a high of .73-.75 last year due to the Ray Branco article. I smelt the hype based on his type and decided to sell at an opportune time. I bought back in at .42 and rode it down to .28 and back up to .35 before I sold. The stock should have more attention and doesn’t get the respect it deserves. Don’t blame me however, for making money when that’s what everyone here who is invested is trying to do. I believe it’s a good time to jump into PMN because I believe the science and believe that there will be good results from the clinical trials. Do I believe management has the shareholders best interest in mind? No, they are trying to run a business and raise capital and I believe would do a PP regardless of what their shareholders think. These guys are in it to make money 1st and help other people 2nd like any other biopharma company. I can believe in a company by not locking up my money or donating it. I believe the last time we had a conversation like this, I had said if you’re not investing to make money, you’re better off donating it.
Bullboard Posts